Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025

Rhea-AI Summary

Aethlon Medical (NASDAQ: AEMD), a medical therapeutic company developing products for cancer and life-threatening infectious diseases, will present at the Emerging Growth Conference on February 19, 2025. The company's CEO, James Frakes, will deliver a 30-minute presentation starting at 11:25 AM Eastern time.

This interactive online event offers shareholders and the investment community the opportunity to engage directly with Mr. Frakes in real-time. Participants can submit questions in advance to Questions@EmergingGrowth.com or during the live session.

For those unable to attend live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel. Registration is required through the provided webcast link to attend and receive updates.

Aethlon Medical invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.

SAN DIEGO, Feb. 13, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 19, 2025.

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with Aethlon Medical's Chief Executive Officer, Mr. James Frakes, in real time.

Mr. Frakes will perform a presentation and may subsequently open the floor for questions. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event and Mr. Frakes will do his best to get through as many of them as possible.

Aethlon Medical, Inc. will be presenting at 11:25 AM Eastern time for 30 minutes.

Please register here to ensure you are able to attend the conference and receive any updates that are released:

https://goto.webcasts.com/starthere.jsp?ei=1696664&tp_key=a17d7ff4c2&sti=aemd

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference. We will release a link to that after the event.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Additional information can be found at www.AethlonMedical.com. 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

 

View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-emerging-growth-conference-on-february-19-2025-302374609.html

SOURCE Aethlon Medical, Inc.

FAQ

When is Aethlon Medical (AEMD) presenting at the Emerging Growth Conference?

Aethlon Medical will present on February 19, 2025, at 11:25 AM Eastern time for 30 minutes.

How can investors participate in AEMD's Emerging Growth Conference presentation?

Investors can register through the provided webcast link to attend the live presentation and can submit questions either in advance via email or during the live event.

What will be discussed at AEMD's February 2025 Emerging Growth Conference presentation?

CEO James Frakes will deliver a presentation about Aethlon Medical, focusing on their development of products to treat cancer and life-threatening infectious diseases, followed by a potential Q&A session.

How can investors watch AEMD's presentation if they miss the live event?

An archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel after the event.

Where can investors submit questions for AEMD's Emerging Growth Conference presentation?

Investors can submit questions in advance to Questions@EmergingGrowth.com or ask them during the live event.